Consent Dismissed: Abbott Labs v. Reckitt Benckiser Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Abbott Laboratories v. Reckitt Benckiser LLC |
| Case Number | 1:14-cv-01511 (N.D. Ill.) |
| Court | U.S. District Court, Northern District of Illinois |
| Duration | Feb 28, 2014 – July 30, 2014 152 days |
| Outcome | Consent Dismissal — Strategic Resolution |
| Patents at Issue | |
| Accused Products | Reckitt Benckiser Analgesic Product Offerings |
Case Overview
The Parties
⚖️ Plaintiff
Globally recognized healthcare and pharmaceutical company with an extensive IP portfolio spanning diagnostics, medical devices, and pharmaceutical products.
🛡️ Defendant
U.S. arm of multinational consumer goods company, dominant in the over-the-counter healthcare market with well-known analgesic product lines.
The Patent at Issue
This litigation centered on U.S. Patent No. 6,926,907, directed to pharmaceutical formulations in the analgesic technology area. The patent covers compositions and methods relevant to pain relief drug delivery — a commercially high-stakes claim space given the scale of the OTC analgesic market.
- • US 6,926,907 — Pharmaceutical formulations for analgesic drug delivery
Developing a new pharmaceutical product?
Ensure your drug formulation doesn’t infringe existing patents. Run a comprehensive FTO analysis.
The Verdict & Legal Analysis
Outcome
The case was terminated via consent dismissal, meaning both Abbott Laboratories and Reckitt Benckiser agreed to dismiss the action. No damages were awarded, no injunction was issued, and no court ruling on infringement or patent validity was rendered. The specific financial or licensing terms of any underlying agreement were not disclosed in public records.
This rapid resolution in just 152 days highlights a strategic approach to managing litigation risk in the pharmaceutical sector, where parties often prioritize negotiated settlements over protracted court battles.
Key Legal Issues
A consent dismissal under Federal Rule of Civil Procedure 41(a) allows parties to terminate litigation by stipulation without court adjudication on the merits. It is neither an admission of liability nor a finding of non-infringement. In pharmaceutical patent disputes, such dismissals frequently accompany confidential licensing, cross-licensing, or covenant not to sue arrangements.
The absence of any merits ruling means U.S. Patent No. 6,926,907 was neither invalidated nor adjudicated infringed. Its enforceability remains legally intact, preserving Abbott’s option to assert the patent in future disputes against different defendants or products.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulation. Choose your next step:
📋 Understand Pharmaceutical Patent Trends
Learn about specific risks and implications from this litigation and broader pharma IP trends.
- View active patents in the analgesic technology space
- Analyze competitor patent portfolios and enforcement patterns
- Understand claim scope and differentiation in drug formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical product or formulation.
- Input your formulation details or technical features
- AI identifies potentially blocking patents in relevant classes
- Get actionable risk assessment report
High Risk Area
Analgesic formulation & drug delivery
Related Patents
In pharmaceutical technology
Strategic Resolution
Possible through licensing/design-around
✅ Key Takeaways
Consent dismissals often signal confidential licensing or commercial agreements, reflecting sophisticated IP risk management.
Search related case law →Early case resolution (152 days) can be a deliberate litigation strategy to preserve patent validity and control costs.
Explore litigation strategies →Frequently Asked Questions
The case involved U.S. Patent No. 6,926,907, covering pharmaceutical formulations in the analgesic technology area.
The parties agreed to a consent dismissal under Fed. R. Civ. P. 41(a). No court ruling on infringement or validity was issued. Settlement terms were not publicly disclosed.
It reinforces that active enforcement of analgesic formulation patents — even when resolved early — signals portfolio strength and can drive licensing outcomes without trial risk.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:14-cv-01511 (N.D. Ill.)
- USPTO Patent Center — U.S. Patent No. 6,926,907
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41(a)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.